New synthetic opioids: Part of a new addiction landscape.
AH-7921
Adverse effects
Fatalities
Fentanyl
MT-45
New psychoactive substances
Psychiatric complications
Somatic complications
Substance use disorder
Synthetic opioids
U-47700
Journal
Neuroscience and biobehavioral reviews
ISSN: 1873-7528
Titre abrégé: Neurosci Biobehav Rev
Pays: United States
ID NLM: 7806090
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
16
02
2018
revised:
14
05
2018
accepted:
12
06
2018
pubmed:
16
9
2018
medline:
4
8
2020
entrez:
16
9
2018
Statut:
ppublish
Résumé
Synthetic opioids (SO) are a major risk for public health across the world. These drugs can be divided into 2 categories, pharmaceutical and non-pharmaceutical fentanyls. A new generation of SO has emerged on the drug market since 2010. North America is currently facing an opioid epidemic of morbi-mortality, caused by over-prescription of opioids, illegally diverted prescribed medicines, the increasing use of heroin and the emergence of SO. Furthermore, this opioid crisis is also seen in Europe. SO are new psychoactive substances characterized by different feature such as easy availability on the Internet, low price, purity, legality, and lack of detection in laboratory tests. They have not been approved or are not recommended for human use. Opioid misuse is associated with somatic and psychiatric complications. For many substances, limited pharmacological information is available, increasing the risk of harmful adverse events. Health actors and the general population need to be clearly informed of the potential risks and consequences of the diffusion and use of SO.
Identifiants
pubmed: 30217656
pii: S0149-7634(18)30114-3
doi: 10.1016/j.neubiorev.2018.06.010
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Synthetic Drugs
0
Fentanyl
UF599785JZ
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
133-140Informations de copyright
Copyright © 2018 Elsevier Ltd. All rights reserved.